

# The drug efficacy and adverse reactions in a mouse model of oral squamous cell carcinoma treated with oxaliplatin at different time points during a day

Kai Yang<sup>1,2</sup>  
Ningbo Zhao<sup>1</sup>  
Dan Zhao<sup>1,2</sup>  
Dan Chen<sup>1</sup>  
Yadong Li<sup>1</sup>

<sup>1</sup>Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, <sup>2</sup>Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing Medical University, Chongqing, People's Republic of China

**Background:** Recent studies have shown that the growth and proliferation of cancer cells *in vivo* exhibit circadian rhythm, and the efficacy and adverse reactions of platinum-based anticancer drugs administered at different times of the day vary significantly on colon cancer. However, since the circadian rhythms of growth and proliferation of various cancer cells often differ, the question of whether the administration of platinum anticancer drugs at different times of the day exerts significantly different efficacy and adverse effects on oral cancers remains to be elucidated. This study has compared the efficacy and adverse effects of oxaliplatin (L-OHP) administration at different times during a day on oral squamous cell carcinoma in mice and has analyzed cellular circadian rhythms.

**Methods:** The mouse model for oral squamous cell carcinoma was established in 75 nude mice, housed in a 12 hour light/12 hour dark cycle environment. The mice were randomly divided into five groups; four experimental groups were intravenously injected with L-OHP at four time points within a 24-hour period (4, 10, 16, and 22 hours after lights on [HALO]). The control group was intravenously injected with the same volume of saline. Treatment efficacy and adverse reactions were compared on the seventh day after the injection, at 22 HALO. The existence of circadian rhythms was determined by cosine analysis.

**Results:** Only injections of L-OHP at 16 and 22 HALO significantly prolonged animal survival time. The adverse reactions in mice injected with L-OHP at 16 and 22 HALO were significantly less than those observed in mice administered L-OHP at 4 and 10 HALO. The cosine fitting curve showed that the survival time and adverse reactions exhibited circadian rhythm.

**Conclusion:** The time factor should be considered when treating patients with oral squamous cell carcinoma with L-OHP in order to achieve better efficacy, reduce the adverse reactions, and improve the patients' survival time and quality of life.

**Keywords:** oral cancer, chronochemotherapy, oxaliplatin, efficacy, adverse reactions, circadian rhythm

## Introduction

Oral cancers account for 2% of cancer incidences in the population, and 90% of those cases are squamous cell carcinoma.<sup>1</sup> Although there has been much progress in the treatment of oral cancers with surgery, chemotherapy, and radiotherapy, the 5-year overall survival rate of oral cancer patients remains only 50%–60%.<sup>1,2</sup> Therefore, to explore novel and effective treatment of oral cancer is of great significance.

Recent studies<sup>3–6</sup> have shown that the growth, proliferation, DNA synthesis, and secretion activities of both normal and tumor cells in mammals display a characteristic

Correspondence: Kai Yang  
Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, No 1, Youyi Road, Yuzhong District, Chongqing 400016, People's Republic of China  
Tel +86 23 8901 2569  
Fax +86 23 8901 2569  
Email cqfyk@hotmail.com

24-hour circadian rhythm. The rhythmic changes in proliferation and DNA synthesis of tumor cells showed an 8–12 hour difference compared to those of normal cells such as bone marrow, gastrointestinal mucosal epithelium, etc. Because proliferating cells with active DNA synthesis are more sensitive to chemotherapeutic drugs, a theoretical rationale is provided for the administration of chemotherapeutic drugs at certain times of day, in order to maximize the killing of cancer cells and minimize the damage to normal cells. Chronochemotherapy is administered by selecting the appropriate medication time based on the differences in circadian rhythm of proliferation and DNA synthesis activities between tumor cells and normal cells in order to obtain the maximum anticancer efficacy, minimize adverse reactions, and improve the patients' survival rate and quality of life.<sup>5,6</sup>

Recent animal experiments and multiple center studies of chronochemotherapy in treating colon cancer, breast cancer, and lung cancer have demonstrated that platinum drugs (cisplatin, carboplatin, and oxaliplatin), 5-fluorouracil, leucovorin, and doxorubicin showed significant differences in anticancer efficacy and adverse reactions when administered at different times during a day.<sup>4–10</sup> The rhythmic changes in growth and proliferation of different tumors often vary.<sup>11</sup> There are no reports regarding the chronochemotherapy against oral cancers; however, our previous studies<sup>12</sup> have shown that the growth and cell proliferation of oral squamous cell carcinoma, *in vivo*, also exhibited the characteristics of circadian rhythm, which implied that there would be great differences in anticancer drug efficacy and adverse reactions with oral squamous cell carcinoma patients when drugs are administered at different times of the day. The results of recent studies are often derived from combinatorial chemotherapy using several anticancer drugs and thus lack the opportunity to observe the efficacy of chronochemotherapy with a single drug. In addition, the previous studies often compared the difference in drug efficacy and adverse reactions for drugs administered at different times during a day, but did not validate and analyze whether there was the characteristic of circadian rhythm.<sup>4–10</sup> Currently, cosine analysis, developed using cosine function modeling, has become an effective method for the analysis of biological rhythmic data. It can exclude the interference of other biological factors, and hence can isolate and visually present the characteristics of the biological rhythm, and show apparent characteristics of circadian rhythm by a cosine fitted curve.<sup>13</sup>

Chemotherapy is an important part of the comprehensive treatment of oral squamous cell carcinoma,<sup>1,2</sup> and platinum-based anticancer drugs are one of the most common and effective drugs for treating almost all solid tumors including

oral cancers.<sup>9,10,14</sup> Recent studies have shown that the efficacy of platinum-based anticancer drugs on colon, breast, and lung cancers, as well as the patients' adverse reactions, vary significantly among drugs administered at different times during a day.<sup>4–10</sup> To explore the effect of chronochemotherapy with platinum anticancer drugs on oral squamous cell carcinoma and its circadian rhythm, this study established an oral squamous cell carcinoma model in nude mice by injecting human oral squamous cell carcinoma Tca8113 cells into mouse cheek. The third generation platinum anticancer drug oxaliplatin (L-OHP) was administered at four different time points during a day, and the respective effects of L-OHP on tumor inhibition rate, survival time, and adverse reactions of the tumor-bearing mice were observed and compared. In order to provide evidence for a safer and more effective application of medications in the clinical treatment of oral cancer, cosine analysis was performed to test for the presence of circadian rhythmicity in the efficacy of drugs administered at different times and in the adverse reactions of corresponding animals.

## Materials and methods

### Reagents and instruments

Oral squamous cell carcinoma cell line Tca8113 was obtained from the College of Life Sciences, Chongqing Medical University (Chongqing, People's Republic of China). Oxaliplatin and Roswell Park Memorial Institute (RPMI) 1640 medium were purchased from Sigma-Aldrich (St Louis, MO, USA). Fetal bovine serum was a product of Life Technologies (Carlsbad, CA, USA), and the microliter centrifuge was a product of HERMLE Labortechnik (Model Z233MK; Wehingen, Germany). An optical microscope used for the analysis of tumor tissue sections was from Nikon Corporation (Model CYMML-EPXFU-068; Tokyo, Japan).

### Experimental animals

A total of 75 specific pathogen free, BALB/c nude mice (females, 5–6-weeks-old, 19–20 g) were purchased from the Experimental Animal Center of Chongqing Medical University. All experimental procedures were approved by the Experimental Animal Use Management Committee, Institute of Experimental Animals, Chongqing Medical University.

### Establishment of the Tca8113 oral squamous cell carcinoma model in nude mice

All of the mice (five per cage) were placed in a standardized 12 hour light/12 hour dark environment, maintained at room temperature ( $24^{\circ}\text{C} \pm 1^{\circ}\text{C}$ ), with an air humidity level of

60% ± 10%. The bedding, feed, and water were all sterilized. The hours after lights on (HALO) was used as a reference: 0 HALO denotes the time the lights go on, and 12 HALO is when lights go off; the time before 12 HALO is the rest phase, and after 12 HALO is the activity phase. All mice were synchronized in the same environment for 3 weeks before the experiment.

Tca8113 cells were cultured with RPMI 1640 medium containing 10% fetal bovine serum in a 37°C incubator with 5% CO<sub>2</sub>. Tca8113 cells in logarithmic growth phase were collected by 0.25% trypsin digestion and centrifuged at 4°C, 1000 rpm (centrifugal radius, 3 cm), for 5 minutes. Cells were then resuspended with sterile phosphate buffered saline into a single cell suspension. A total of 0.2 mL of Tca8113 cell suspension containing 2 × 10<sup>6</sup> cells was injected into the cheek of nude mice, which were then placed in the same standardized 12 hour light/12 hour dark environment in separate cages. The growth of implanted tumors was observed daily. Three weeks later, evident tumors were observed and the experiments were started.

## Drug administration and timing

According to the random number table, the 75 tumor-bearing nude mice were divided into five groups (four experimental groups and one control group, with 15 animals in each group). L-OHP powder was dissolved with 0.9% saline to a concentration of 3.4 mg/mL. Mice from each of the four experimental groups were injected, via the tail vein, with L-OHP solution (17 mg/kg) within a 24-hour period at 4, 10, 16, and 22 HALO. The control group was injected with the same volume of 0.9% saline.

## Efficacy evaluation

At 22 HALO on the seventh day after drug administration, the maximum and minimum diameters of the tumors in the five groups of animals were measured with a vernier caliper. The tumor volume (V) was calculated as follows,

$$V = 0.5ab^2 \quad (1)$$

where a and b are the maximum and minimum of the diameters of the tumors, respectively. The following equation was used to determine tumor inhibition rate,

$$\frac{\text{Mean V of control group} - \text{Mean V of the treatment group}}{\text{Mean tumor volume of the control group}} \times 100\% \quad (2)$$

The survival time was determined as the number of days that each tumor-bearing mouse survived after the drug administration.

## Adverse reactions

The adverse reactions were assessed using the following indexes: peripheral white blood cell (WBC) count, body weight of tumor-bearing mice, and rate of perianal swelling. Briefly, at 22 HALO on the seventh day after drug administration, mouse body weight was measured with an electronic weighing scale. The perianal swelling of nude mice was observed,<sup>15,16</sup> and 20 µL of venous blood was drawn from the tail vein of mice by puncture with a clean, dry trace hemoglobin pipette, and peripheral WBCs were counted manually using a hemocytometer.

## Statistical analysis

The data were analyzed using SigmaPlot 12.0 software (Systat Software, Inc, San Jose, CA, USA). The comparison between multiple means was performed with analysis of variance, while the comparison between rates was carried out using  $\chi^2$  test. Cosine analysis was done using CircWave V1.4 software (Groningen, The Netherlands) to test whether there was circadian rhythm with each indicator. Survival times among groups were tested by Kaplan–Meier survival curves. The results were presented as mean ± standard deviation, and differences with  $P < 0.05$  were considered statistically significant.


## Results

### Histological examination of Tca8113 tumors formed in nude mice

Tumor formation was evident in the cheeks of all 75 nude mice 3 weeks after the implantation of Tca8113 cells. A large amount of tumor cells were visible under the light microscope in sections of tumor tissues stained with hematoxylin and eosin. Tumor cells were poorly differentiated and arranged tightly, and the formation of tumor nests was also observed (Figure 1).

### Comparison of tumor inhibition rate among groups of tumor-bearing mice

The tumor inhibition rate of each group is shown in Table 1, which exhibits significant differences among groups administered L-OHP at various time points of the day ( $\chi^2 = 50.49$ ,  $P = 0.00$ ). Injection of L-OHP at 10 HALO showed the minimum inhibitory rate, which was significantly lower than those of 4, 16, and 22 HALO groups; however, the tumor inhibition rates were not significantly different among the 4, 16, and 22 HALO groups ( $P > 0.05$ ).



**Figure 1** Pathological section of tumor formed 3 weeks after the inoculation of Tca8113 cells into the cheek of nude mice (hematoxylin and eosin stain, ×200).

### Comparison of survival time among groups of tumor-bearing mice

The mean survival time of tumor-bearing mice in each group is shown in Table 1, which indicates that there was significant difference in the mean survival time among groups of tumor-bearing mice ( $F = 15.02, P < 0.001$ ). However, the animal survival times in the 4 and 10 HALO groups showed no significant difference compared with that of the control group ( $P > 0.05$ ), indicating that injection of L-OHP at 4 and 10 HALO did not significantly prolong animal survival time. In contrast, the animal survival times in the 16 and 22 HALO groups were significantly different from that in the control group ( $P < 0.05$ ), suggesting that injection of L-OHP at 16 and 22 HALO significantly extended the survival time of tumor-bearing mice, while the animal survival times between the 16 and 22 HALO groups showed no significant

**Table 1** Drug efficacy and adverse reactions in control and experimental tumor-bearing mice 7 days after L-OHP injection

	Control group	L-OHP treatment groups			
		4 HALO	10 HALO	16 HALO	22 HALO
Tumor inhibition rate (%)	0.00	23.97	7.05	31.55	28.33
Survival time (days), mean ± SD	9.85 ± 2.80	14.07 ± 4.02	10.73 ± 3.51	20.73 ± 5.41	17.33 ± 6.11
WBC count ( $10^3$ cells/ $\mu$ L), mean ± SD	16.54 ± 0.20	14.34 ± 0.23	14.18 ± 0.25	15.40 ± 0.2	14.98 ± 0.18
Body weight (g), mean ± SD	17.32 ± 0.12	17.48 ± 0.07	17.35 ± 0.10	17.91 ± 0.18	17.55 ± 0.13
Perianal swelling (%) [n/15]	0.00 [0/15]	46.67 [7/15]	60.00 [9/15]	13.33 [2/15]	26.67 [4/15]

**Abbreviations:** L-OHP, oxaliplatin; HALO, hours after light onset; WBC, white blood cell; SD, standard deviation.


difference ( $P > 0.05$ ). These data clearly suggest that injection of L-OHP during the activity phase can significantly extend the survival time of tumor-bearing mice.

Cosine analysis also indicates that there is circadian rhythmicity in the mean survival time of tumor-bearing mice injected with L-OHP at various times ( $F = 12.47, P < 0.001$ ). As shown in Figure 2, the cosine fitting curve suggests that tumor-bearing mice injected with L-OHP at 6.98 HALO have the shortest survival time (11.03 days), while tumor-bearing mice injected with L-OHP at 18.97 HALO display the longest survival time (20.41 days).

Kaplan–Meier survival curve analysis indicates that tumor-bearing nude mice injected with L-OHP at 10 HALO had the shortest survival time, while the longest survival time was observed in animals injected with L-OHP at 16 HALO (log-rank  $\chi^2 = 27.36, P < 0.001$ ).

### Comparison of the adverse reactions among groups of tumor-bearing mice

The data collected from WBC count, body weight, and perianal swelling are shown in Table 1. The WBC counts were significantly different among the five groups of tumor-bearing mice ( $F = 292.21, P < 0.001$ ), and the WBC counts in the four experimental groups were significantly lower than that in the control group ( $P < 0.001$ ). The lowest WBC count was measured in animals injected with L-OHP at 10 HALO, while the WBC count least reduced from control levels was observed in mice injected L-OHP at 16 HALO.



**Figure 2** Cosine fitting curve of the survival times of tumor-bearing mice injected with L-OHP at four different time points.


**Notes:** The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average survival time in each group (n = 15) of tumor-bearing mice that received L-OHP at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance,  $F = 15.02, P < 0.001$ ; circadian rhythm was tested with cosine analysis,  $F = 12.47, P < 0.001$ .

**Abbreviations:** L-OHP, oxaliplatin; HALO, hours after light onset.

Cosine analysis shows that circadian rhythm was involved with the reduction in WBC count among animals injected with L-OHP at different times ( $F = 100.25$ ,  $P = 0.00$ ). Cosine curve fitting (Figure 3) also indicates that mice injected with L-OHP at 18.52 HALO show the least reduction in WBC count from the control levels ( $15.43 \times 10^3$  cells/ $\mu$ L), while mice injected with L-OHP at 6.46 HALO suffer the most severe reduction in WBC count ( $14.19 \times 10^3$  cells/ $\mu$ L).

The body weight of tumor-bearing mice showed significant differences among the five groups ( $F = 51.87$ ,  $P < 0.001$ ). The body weight of mice in the 10 HALO group was similar to that in the control group ( $P > 0.05$ ), whereas the body weight of animals in the 4, 16, and 22 HALO groups was significantly different from that of the control group ( $P < 0.05$ ). However, there was no significant difference in body weight between the 4 and 22 HALO groups ( $P > 0.05$ ), whereas the body weight of animals in the 16 HALO group was significantly different from that in the 4 and 22 HALO groups ( $P < 0.05$ ). Cosine analysis indicates that there is circadian rhythmicity in body weight of mice injected with L-OHP at different time points ( $F = 24.61$ ,  $P = 0.00$ ), and cosine curve fitting (Figure 4) shows that mice injected with L-OHP at 17.75 HALO have the highest body weight (17.81 g), whereas animals injected with L-OHP at 5.81 HALO have the lowest body weight (17.32 g).


The rate of perianal swelling was significantly different among the five groups of tumor-bearing mice ( $\chi^2 = 17.11$ ,  $P < 0.01$ ), the highest of which was seen in mice injected



**Figure 3** Cosine fitting curve of the WBC counts of tumor-bearing mice injected with L-OHP at four different time points.

**Notes:** The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average WBC counts in each group ( $n = 15$ ) of tumor-bearing mice at 22 HALO 7 days after L-OHP injection at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance,  $F = 292.21$ ,  $P < 0.001$ ; circadian rhythm was tested with cosine analysis,  $F = 100.25$ ,  $P = 0.00$ .

**Abbreviations:** L-OHP, oxaliplatin; HALO, hours after light onset; WBC, white blood cell.



**Figure 4** Cosine fitting curve of the body weights of tumor-bearing mice injected with L-OHP at four different time points.

**Notes:** The segment of hatched bar on the x axis represents activity phase. The four points in the figure represent the average body weight in each group ( $n = 15$ ) of tumor-bearing mice at 22 HALO 7 days after L-OHP injection at 4, 10, 16, 22 HALO in a day. The points represent the means, and bars represent standard deviation; the comparison between multiple means was performed with analysis of variance,  $F = 51.87$ ,  $P < 0.001$ ; circadian rhythm was tested with cosine analysis,  $F = 24.61$ ,  $P = 0.00$ .

**Abbreviations:** L-OHP, oxaliplatin; HALO, hours after light onset.

with L-OHP at 10 HALO (60.00%, 9/15), and the lowest rate was in the 16 HALO group (13.33%, 2/15). The rate of perianal swelling in the 16 HALO group was significantly different from that of the 4 and 10 HALO groups ( $P < 0.05$ ) but not from that of the 22 HALO group ( $P > 0.05$ ), indicating that injection of L-OHP during the activity phase significantly reduces the perianal swelling rate in tumor-bearing mice compared with drug injections administered during the rest phase.

## Discussion

L-OHP is a third generation platinum anticancer drug, containing a ring of 1,2-diaminocyclohexane. After activation, the ring and platinum in L-OHP bind to DNA in cancer cells and form a platinum-DNA complex as well as intra- and interstrand crosslinks, thereby blocking DNA replication and transcription, resulting in noncell cycle-specific death.<sup>17</sup> Currently, L-OHP is often applied in combination with other anticancer drugs. In this study, however, L-OHP treatment alone was used, in order to better discern the circadian characteristics of L-OHP in treating oral squamous cell carcinoma. We found that the tumor inhibition rates at 7 days after the injection of L-OHP at four different time points (4, 10, 16, and 22 HALO), within a 24-hour period were 23.97%, 7.05%, 31.55%, and 28.33%, respectively, while the corresponding survival times were  $14.07 \pm 4.02$ ,  $10.73 \pm 3.51$ ,  $20.73 \pm 5.41$ , and  $17.33 \pm 6.11$  days, respectively. The tumor inhibition rate and survival time in the 10 HALO group was significantly

lower than that in other treatment groups. Although the 4 HALO group showed a similar tumor inhibition rate compared with the 16 and 22 HALO groups, only injections with L-OHP at 16 and 22 HALO significantly prolonged the survival time of tumor-bearing mice. Also, cosine analysis proved a role for circadian rhythmicity in average survival time of mice injected with L-OHP at different time points, ie, tumor-bearing mice injected with L-OHP at 6.98 HALO (middle rest phase) had the shortest survival time (11.03 days), while animals injected with L-OHP at 18.97 HALO (middle activity phase) showed the longest survival time (20.41 days).

Because myelosuppression and gastrointestinal mucosal epithelial damage are major adverse reactions to L-OHP,<sup>17</sup> the present study used indexes such as body weight (reflecting physical condition), WBC count (reflecting bone marrow suppression), and perianal swelling (reflecting gastrointestinal toxicity) to evaluate adverse reactions of experimental animals.<sup>16,17</sup> All three indexes showed significant differences among animals injected with L-OHP at four different time points (4, 10, 16, and 22 HALO). The lowest body weight was observed in mice injected with L-OHP at 10 HALO, whereas mice injected with L-OHP at 16 HALO showed the highest body weight, suggesting the minimal detrimental impact of L-OHP injection at 16 HALO on the general physical condition of mice. Cosine analysis indicates the circadian rhythmicity in body weight of mice injected with L-OHP at different time points, ie, injection of L-OHP at 17.75 HALO (middle activity phase) exerts minimal impact on the body weight of tumor-bearing animals, whereas injection of L-OHP at 5.81 HALO (middle rest phase) shows the greatest impact on the body weight of tumor-bearing mice. The results of WBC count also indicated that the most reduction in WBC count was in animals injected with L-OHP at 10 HALO, while the 16 HALO group showed the least reduction in WBC count as compared to controls, implying that injection of L-OHP at 16 HALO exerts the least suppression on mouse bone marrow. Cosine analysis also indicates the existence of circadian rhythm in WBC counts of mice injected with L-OHP at different time points, ie, L-OHP injection at 18.52 HALO (mid activity phase) resulted in the least reduction in WBC count (ie, least bone marrow suppression), whereas injection of L-OHP at 6.46 HALO (middle rest phase) led to the most reduction in WBC count (ie, most severe bone marrow suppression). The results of perianal swelling showed that injection of L-OHP at 10 HALO (late rest phase) led to the highest incidence rate of perianal swelling (60.00%), indicating the greatest toxic effect on the gastrointestinal tract, while

L-OHP injection at 16 HALO (transition from early to middle activity phase) resulted in the lowest rate of perianal swelling (13.33%) (ie, the lowest gastrointestinal toxicity).

The mechanism of the circadian effects of L-OHP is closely related to the circadian variations of cancer cell proliferation, cell cycle distribution, DNA synthesis, drug-metabolizing enzyme activity, blood flow in tumor tissue, and other factors.<sup>3-6</sup> Since L-OHP can easily form crosslinks with the DNA of cancer cells, injection of L-OHP in the phase of high cancer cell proliferation and high DNA synthesis can elicit greater anti-cancer effects.<sup>6,17</sup> However, alterations in circadian rhythms of cancer cell proliferation and DNA synthesis seem to depend upon tumor type, growth rate, and level of differentiation.<sup>6,11</sup> Blumenthal et al<sup>18</sup> reported that blood flow in tumors and normal organs of tumor-bearing mice had circadian rhythms. Blood flow in mouse tumors was significantly higher during 15–21 HALO than during 3–9 HALO, and tumor blood flow reached peak value at 17 HALO, whereas the circadian rhythm of blood flow in normal organs (such as liver, lung, and kidney) was opposite to that in tumors. Since the circadian rhythm variations of blood flow in tumors and normal organs can affect the local concentration of drug, it then can affect drug efficacy and adverse reactions of a drug given at different times in a day.<sup>18,19</sup> Reduced glutathione, which can reverse cytotoxic effects of platinum drugs, also has circadian rhythm.<sup>20-22</sup> This may be one of the reasons for different drug efficacy and adverse reactions of L-OHP injected at different times in a day. Therefore, the different drug efficacy and adverse reaction results observed in this study are consistent with the overall conclusions resulting from the combination of the aforementioned factors. The details of the specific mechanism remains the focus of further in-depth study.

Currently, a growing number of researchers recognize that a reasonable time regimen for the administration of anticancer drugs plays an equally important role as does the drug dosage.<sup>23</sup> This study has shown that injection of L-OHP at different time points during a day resulted in significantly different efficacy and adverse reactions in treating oral squamous cell carcinoma in mice. Such differences fluctuated with a 24 hour circadian rhythm, and injections of L-OHP at 16 and 22 HALO significantly prolonged the survival time in mice with oral squamous cell carcinoma. In general, injection of L-OHP in the early and middle activity phases achieved the maximum efficacy and minimum adverse reactions, whereas injection of L-OHP in the early and middle rest phases led to the worst efficacy and maximum adverse reactions. Although the rodents are nocturnal animals, and

their phases of rest and activity are contrary to those of human beings, recent studies have shown<sup>5,6,24</sup> that the experimental results obtained from the rest and activity phases of rodents can be directly extended to the corresponding rest and activity phases in humans. Therefore, circadian time factors should be considered when applying chemotherapy in patients with oral squamous cell carcinoma, in order to achieve better efficacy, reduce toxic effect, and improve patients' survival time and quality of life.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Kademi D, Bell RB, Schmidt BL, et al. Oral and maxillofacial surgeons treating oral cancer: a preliminary report from the American Association of Oral and Maxillofacial Surgeons Task Force on Oral Cancer. *J Oral Maxillofac Surg.* 2008;66(10):2151–2157.
- Kademi D, Bell RB, Bagheri S, et al. Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. *J Oral Maxillofac Surg.* 2005;63(11):1599–1605.
- Eismann EA, Lush E, Sephton SE. Circadian effects in cancer-relevant psychoneuroendocrine and immune pathways. *Psychoneuroendocrinology.* 2010;35(7):963–976.
- Huang XL, Fu CJ, Bu RF. Role of circadian clocks in the development and therapeutics of cancer. *J Int Med Res.* 2011;39(6):2061–2066.
- Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. *Annu Rev Pharmacol Toxicol.* 2010;50:377–421.
- Lévi F. Chronotherapeutics: the relevance of timing in cancer therapy. *Cancer Causes Control.* 2006;17(4):611–621.
- Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. *Lancet.* 1997;350(9079):681–686.
- Lemmer B. Chronobiology, drug-delivery, and chronotherapeutics. *Adv Drug Deliv Rev.* 2007;59(9–10):825–827.
- Santini D, Vincenzi B, Schiavon G, et al. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. *Cancer Chemother Pharmacol.* 2007;59(5):613–620.
- Garufi C, Brienza S, Pugliese P, et al. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. *Anticancer Drugs.* 2000;11(6):495–501.
- Davidson AJ, Straume M, Block GD, Menaker M. Daily timed meals dissociate circadian rhythms in hepatoma and healthy host liver. *Int J Cancer.* 2006;118(7):1623–1627.
- Zhao N, Tang H, Yang K, Chen D. Circadian rhythm characteristics of oral squamous cell carcinoma growth in an orthotopic xenograft model. *Onco Targets Ther.* 2013;6:41–46.
- Manoharan S, Baskar AA, Manivasagam T, Subramanian P. Circadian rhythmicity of plasma lipid peroxidation and antioxidants in oral squamous cell carcinoma. *Singapore Med J.* 2005;46(4):184–188.
- Kelland L. The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer.* 2007;7(8):573–584.
- Singletary J, Wood PA, Du-Quiton J, et al. Imaging multidimensional therapeutically relevant circadian relationships. *Int J Biomed Imaging.* 2009;2009:231539.
- Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. *Mol Cancer Ther.* 2006;5(8):2023–2033.
- Kelland L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. *Expert Opin Investig Drugs.* 2007;16(7):1009–1021.
- Blumenthal RD, Osorio L, Ochakovskaya R, Ying Z, Goldenberg DM. Regulation of tumour drug delivery by blood flow chronobiology. *Eur J Cancer.* 2000;36(14):1876–1884.
- Hori K, Zhang QH, Li HC, Saito S, Sato Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. *Int J Cancer.* 1996;65(3):360–364.
- Lévi F, Focan C, Karaboué A, et al. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. *Adv Drug Deliv Rev.* 2007;59(9–10):1015–1035.
- Zeng ZL, Sun J, Guo, L, et al. Circadian rhythm in dihydropyrimidine dehydrogenase activity and reduced glutathione content in peripheral blood of nasopharyngeal carcinoma patients. *Chronobiol Int.* 2005;22(4):741–754.
- Granda TG, Lévi F. Tumor-based rhythms of anticancer efficacy in experimental models. *Chronobiol Int.* 2002;19(1):21–24.
- Vincenzi B, Santini D, La Cesa A, Tonini G. Cancer chronotherapy: principles, applications, and perspectives. *Cancer.* 2003;98(4):881–883.
- Innominato PF, Lévi FA, Bjarnason GA. Chronotherapy and the molecular clock: clinical implications in oncology. *Adv Drug Deliv Rev.* 2010;62(9–10):979–1001.

### Drug Design, Development and Therapy

### Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which

Submit your manuscript here: <http://www.dovepress.com/drug-design-development-and-therapy-journal>

Dovepress

has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.